| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Alex Louis, senior vice president of enterprise operations and operational excellence at Quest Diagnostics, shares more on how thoughtful planning is essential for successful automation implementation as clinical labs face growing pressure. Clinical laboratories in the US have long operated under significant pressure and challenges, and these have only intensified in recent times. Many laboratory leaders are now facing issues around workflow, staffing, and productivity. Improving the patient and customer experience is also a growing concern, so how can clinical laboratory leaders address these challenges quickly and smoothly?
Although nearly half of Americans know their streaming platform passwords by heart, only 19% are aware of what their cholesterol score is, according to new data from Quest Diagnostics. As part of its second “Know Your Health” survey, the Secaucus-based testing provider explored what perceptions and priorities adults have for their well-being in 2025. After surveying nearly 2,100 individuals, Quest found that 92% of respondents want to take a more active role in their health care journey. However, many said they face obstacles to receiving care, their doctors do not focus enough on preventive care discussions or have gaps in knowledge on important personal health information.
A new report reveals oncologists are seeing more advanced cancer cases due to screening barriers and are concerned current tests aren’t effective enough for early detection of recurrence. Takeaways: Screening barriers are seen as the leading cause of late-stage cancer diagnoses; Oncologists express concern that current monitoring tools may not detect cancer recurrence early; ctDNA MRD tests, like Quest’s new Haystack MRD, show promise in improving post-treatment cancer surveillance.
For decades now, consolidation has been one of the major trends in the clinical laboratory market as major players have grown their businesses through the acquisition of smaller independent and hospital labs. While much of this action has focused on the US market, these firms are looking internationally, as well, striking a number of recent deals to expand their footprints abroad. Last year, for instance, Quest acquired Canadian laboratory firm LifeLabs for roughly $985 million, giving the company a major presence in that country. Karthik Kuppusamy, senior VP of clinical solutions at Quest, said the firm sees opportunities to expand the LifeLabs business by moving into provinces not currently served by the company, winning business currently being done by hospital labs, and introducing new advanced diagnostics into the market.
Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related to Alzheimer’s disease in individuals with mild cognitive impairment (MCI) or dementia. The test, known as AD-Detect Abeta 42/40 and p-tau217 Evaluation, is said to combine amyloid beta (AB) 42/40 blood level outcomes, which are determined by Quest’s tandem mass spectrometry techniques with p-tau217 blood levels as measured by an in vitro immunoassay.